Analysis of the LKB1-STRAD-MO25 complex
- PMID: 15561763
- DOI: 10.1242/jcs.01571
Analysis of the LKB1-STRAD-MO25 complex
Abstract
Mutations in the LKB1 tumour suppressor threonine kinase cause the inherited Peutz-Jeghers cancer syndrome and are also observed in some sporadic cancers. Recent work indicates that LKB1 exerts effects on metabolism, polarity and proliferation by phosphorylating and activating protein kinases belonging to the AMPK subfamily. In vivo, LKB1 forms a complex with STRAD, an inactive pseudokinase, and MO25, an armadillo repeat scaffolding-like protein. Binding of LKB1 to STRAD-MO25 activates LKB1 and re-localises it from the nucleus to the cytoplasm. To learn more about the inherent properties of the LKB1-STRAD-MO25 complex, we first investigated the activity of 34 point mutants of LKB1 found in human cancers and their ability to interact with STRAD and MO25. Interestingly, 12 of these mutants failed to interact with STRAD-MO25. Performing mutagenesis analysis, we defined two binding sites located on opposite surfaces of MO25alpha, which are required for the assembly of MO25alpha into a complex with STRADalpha and LKB1. In addition, we demonstrate that LKB1 does not require phosphorylation of its own T-loop to be activated by STRADalpha-MO25alpha, and discuss the possibility that this unusual mechanism of regulation arises from LKB1 functioning as an upstream kinase. Finally, we establish that STRADalpha, despite being catalytically inactive, is still capable of binding ATP with high affinity, but that this is not required for activation of LKB1. Taken together, our findings reinforce the functional importance of the binding of LKB1 to STRAD, and provide a greater understanding of the mechanism by which LKB1 is regulated and activated through its interaction with STRAD and MO25.
Similar articles
-
ATP and MO25alpha regulate the conformational state of the STRADalpha pseudokinase and activation of the LKB1 tumour suppressor.PLoS Biol. 2009 Jun 9;7(6):e1000126. doi: 10.1371/journal.pbio.1000126. Epub 2009 Jun 9. PLoS Biol. 2009. PMID: 19513107 Free PMC article.
-
MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm.EMBO J. 2003 Oct 1;22(19):5102-14. doi: 10.1093/emboj/cdg490. EMBO J. 2003. PMID: 14517248 Free PMC article.
-
Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade.J Biol. 2003;2(4):28. doi: 10.1186/1475-4924-2-28. Epub 2003 Sep 24. J Biol. 2003. PMID: 14511394 Free PMC article.
-
LKB1-dependent signaling pathways.Annu Rev Biochem. 2006;75:137-63. doi: 10.1146/annurev.biochem.75.103004.142702. Annu Rev Biochem. 2006. PMID: 16756488 Review.
-
LKB1 biology: assessing the therapeutic relevancy of LKB1 inhibitors.Cell Commun Signal. 2024 Jun 6;22(1):310. doi: 10.1186/s12964-024-01689-5. Cell Commun Signal. 2024. PMID: 38844908 Free PMC article. Review.
Cited by
-
ATP and MO25alpha regulate the conformational state of the STRADalpha pseudokinase and activation of the LKB1 tumour suppressor.PLoS Biol. 2009 Jun 9;7(6):e1000126. doi: 10.1371/journal.pbio.1000126. Epub 2009 Jun 9. PLoS Biol. 2009. PMID: 19513107 Free PMC article.
-
STRADalpha regulates LKB1 localization by blocking access to importin-alpha, and by association with Crm1 and exportin-7.Mol Biol Cell. 2008 Apr;19(4):1614-26. doi: 10.1091/mbc.e07-05-0454. Epub 2008 Feb 6. Mol Biol Cell. 2008. PMID: 18256292 Free PMC article.
-
A mouse model uncovers LKB1 as an UVB-induced DNA damage sensor mediating CDKN1A (p21WAF1/CIP1) degradation.PLoS Genet. 2014 Oct 16;10(10):e1004721. doi: 10.1371/journal.pgen.1004721. eCollection 2014 Oct. PLoS Genet. 2014. PMID: 25329316 Free PMC article.
-
Structure of the 14-3-3ζ-LKB1 fusion protein provides insight into a novel ligand-binding mode of 14-3-3.Acta Crystallogr F Struct Biol Commun. 2015 Sep;71(Pt 9):1114-9. doi: 10.1107/S2053230X15012595. Epub 2015 Aug 25. Acta Crystallogr F Struct Biol Commun. 2015. PMID: 26323294 Free PMC article.
-
Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity.Signal Transduct Target Ther. 2024 Jan 5;9(1):11. doi: 10.1038/s41392-023-01706-y. Signal Transduct Target Ther. 2024. PMID: 38177135 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources